Progyny (PGNY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.52
- Estimate
- $0.51
- Surprise
- +2.2%
- Score today
- 6.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Progyny (PGNY) beat the $0.51 estimate with adjusted EPS of $0.52 — a modest 2.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PGNY Hold at 6.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +2.2% surprise compares with a +10.7% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Target reached (-0.5% upside)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $30.10
- Stop
- $28.30
The stock trades at 32.7× trailing but 13.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
PGNY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Healthcare Plans
- Market cap
- $2.31B
- P/E (fwd)
- 13.0
- P/E (ttm)
- 32.7
- 52-week range
- $16.10–$33.06
- Off 52-week high
- 9.0%
- RSI (14)
- 67
- Volume vs avg
- 1.36×
- Score today
- 6.1/10